

Hepatic Encephalopathy

Mamdouh Gabr
Tanta University,
Egypt.

Definition

- Complex neuropsychiatric syndrome complicating advanced liver disease and/or portosystemic shunting (1990s)
- Complex neuropsychiatric syndrome caused by portosystemic venous shunting with or without intrinsic liver disease (M C North Am 2008)
- Complex neuropsychiatric syndrome complicating acute and chronic liver failure (Schliess etal 2009)

Pathogenesis

- The pathogenesis of HE remains poorly understood (WJ Gastroenterol 2008)
- HE in liver cirrhosis is a clinical manifestation of a low-grade cerebral edema, which is exacerbated in response to ammonia and other neurotoxins (Haussinger D et al, 2008)

- The accumulation of **ammonia** and other **neurotoxins** in the systemic circulation is the main pathogenic factor in **HE**.
- Normally, these **neurotoxins** are produced (**gut bacteria**) and absorbed from the **gut** and cleared by the **liver**.
- When **liver** function is seriously impaired (**Acute** or **Chronic LF**), these **neurotoxins** bypass the **liver** and gain access to the systemic circulation, cross the blood-brain barrier, and accumulate in the **CNS**.

- Unchanged ammonia traverses the BBB, and enter the parenchymal cells (especially astrocytes), where it is converted into glutamine.
- Glutamine in turn has osmolar activity and increases the cell water content, contributing to cerebral edema.
- Therefore, ammonia plays the key role in the pathogenesis of HE by inducing astrocyte swelling and/or sensitizing astrocytes to swelling by a heterogeneous panel of precipitating factors and conditions (Chleiss F et al 2009)

- ◉ Whereas **astrocyte swelling** is so marked in **ALF** and leads to clinically **overt** brain edema, a low grade glial edema without clinically overt brain edema is observed in **HE** complicating **liver cirrhosis** (**Chronic LCF**).
- ◉ This **overt** brain edema in **ALF** may lead to increased intracranial pressure and potentially, brain **herniation**.

- Swelling of astrocytes produces reactive oxygen and nitrogen oxide species (ROS/RNOS), which again increases astrocyte swelling and subsequently induces RNA oxidation that may impair postsynaptic protein synthesis, which is required for memory formation and offers a novel explanation for multiple disturbances of the neurotransmitter systems, gene expression, motor and cognitive deficits observed in HE

(Schliess et al 2009)

Clinical significance and Magnitude of the problem

- About $1/3$ to $1/2$ of hospitalizations for cirrhosis are related to HE
- Patients with HE often have other manifestations of ESLD, however HE can also develop as an isolated manifestation of decompensated cirrhosis.
- Hepatic encephalopathy may disable the patient from employment, driving and self care.
- HE usually signals advanced liver disease and consequently is often considered a clinical indication for liver transplantation

Types of hepatic encephalopathy

HE

Type A



FHF

Type B



Normal Liver
PV obst + shunt

Type C



Cirrhosis
with/without shunt

Episodic



Ppt factors



Correction



Resolution of HE episode

Persistent
Lasting > 4w

Minimal HE
"subclinical"

80%

QOL → car accidents

Overt HE

PPT factors for HE

- GI bleeding
- Infections: (SBP, UTI, chest, skin)
- Constipation
- Excessive dietary proteins
- Electrolyte disturbance: (Hypokalemia, Hyponatremia)
- Superimposed liver injury: (acute viral hepatitis, drugs)
- Surgery
- CNS depressant drugs
- HCC
- Dehydration
- Renal failure
- TIPS

Clinical staging of HE

(MCNA 2008)

- An objective, simple, specific and sensitive method to diagnose the severity of HE has not yet been devised

Grade	Findings
<p>Grade 0 MHE</p>	<ul style="list-style-type: none"> ✓ Subclinical. ✓ No abnormality
<p>Grade I Mild</p>	<ul style="list-style-type: none"> ➤ Inverted sleep pattern ➤ Shortened attention span ➤ Impaired addition and subtraction ➤ Euphoria, depression, irritability ➤ Impaired handwriting (incoordination)
<p>Grade II Moderate</p>	<ul style="list-style-type: none"> ✓ Lethargy, intermittent disorientation (time) ✓ Personality changes ✓ Asterexis (flapping)
<p>Grade III Severe</p>	<ul style="list-style-type: none"> ➤ Slurred speech ➤ Somnolence, semistupor ➤ Complete disorientation (time, place) ➤ Paranoia + bizarre behavior ➤ ↑ reflexes + babiniski's sign
<p>Grade IV Coma</p>	<p>With or without response to stimuli</p>

Diagnosis & differential diagnosis

- ◉ **Suspect** in any liver disease patient presenting with **mental changes** ?
- ◉ **HE** is usually preceded by **ppt** factor
- ◉ **Asterexis** = flapping tremors
 - Stage II
 - Weakens in stage III
 - Disappears in **coma**

○ Seizures and focal neurological signs are uncommon manifestation of HE →

warrants appropriate brain imaging →

Structural brain damage →

Subdural hematoma



Major differential diagnoses in HE

- Other metabolic encephalopathies:
 - > Uremic
 - > Hypoglycemia
 - > Ketoacidosis
 - > Hypoxia
 - > Thyroid dysfunction
- CNS infections (meningitis, encephalitis)
- Ischemic brain disease (TIAs, Ischemic strokes)
- CNS tumors

Investigations

- Overt HE from history and clinical examination

○ Diagnosis not clear or in question



- Blood ammonia level
- Brain imaging (CT, MRI)
- EEG
- Psychometric tests (MHE)

Blood ammonia

- ◉ Previously, discrepancy between blood ammonia level and severity of HE
- ◉ Currently; properly processed blood ammonia levels correlate well with the severity of HE

Problems in biochemical assay of ammonia:

- Labile → spontaneous determination + evaporation at room temp
- Venous blood ammonia correlates well with arterial ammonia when properly assessed
- Samples must be withdrawn in heparinized container, placed in ice and assayed within 30 min

Concerns

- Normal blood ammonia level doesn't support the diagnosis of HE
- Conversely, an elevated ammonia level in a comatose patient doesn't exclude a coexistent condition
- However, markedly elevated blood ammonia (> 150 – 200 $\mu\text{mol/l}$) → strongly suspicious of HE
- Blood ammonia is moderately elevated in cirrhotics without HE

Management

◎ PPT factors:

- > Dehydration
- > GIB
- > Infection
- > Electrolyte disturbance
 - Hypokalemia
 - Hyponatremia

◎ Artificial liver support

◎ Ammonia

- > ↓ production + absorption
 - Diet
 - Lactulose + lactitol
 - Oral antibiotics
- > ↑ ammonia clearance
 - L ornithine – L – Aspartate

◎ Liver transplantation

A) PPT factors

- ◎ Dehydration:
 - > Stop diuretics
 - > IV physiologic saline

A) PPT factors

- GI bleeding:

A) PPT factors

◎ Infection

- > SBP
- > UT
- > Chest

A) PPT factors

◎ Electrolyte disturbance

- > Hypokalemia → IV k
- > Hyponatremia → hypertonic saline

(150 ml of 3% NaCl IV)

(S. sodium < 125 mEq/L)

- Any episode of **HE** is considered due to **ESLD** only after exclusion of any **ppt factor**

B) Ammonia

There can be little doubt that **ammonia**, by both direct and indirect mechanisms plays the major role in the pathogenesis of **HE** in both **acute** and **chronic LF**

◎ ↓ Production of gut ammonia

> Diet

- Excessive dietary protein can ppt HE
- Patients with compensated cirrhosis:
 - No restriction
 - Diet containing 1.2 gm protein/kg/ day is recommended

(MCNA, 2008)

- HE episode →
 - Protein restriction to 40 gm/ day is advocated not more than 48 hours and then minimized
 - Prolonged protein restriction in HE → can exacerbate the catabolic state of cirrhosis → release of AA and other nitrogenated byproducts from the muscles
 - Cordoba et al, 2004: found no difference in the improvement of the mental functions in 2 groups of patients with severe HE treated with low and high protein diet

○ Chronic HE

- Vegetable proteins are better tolerated than animal proteins:
 - ✓ ↑ content of dietary fibers → natural cathartic
 - ✓ ↓ levels of AA acids → false transmitters
- Supplementation with oral branched chain AAs → improves survival and QOL (expensive)


(Mesejo et al, 2008)

> Lactulose or lactitol (cathartics)

- Lactulose (beta – galactosido fructose)
- Lactitol (beta – galactosido sorbitol)

Lactulose & lactitol

Non absorbable disaccharides



Dose

Orally
30 ml/2-4 times/day
(stage I, II)



3 – 5 loose
motions

Enema or NGT
300 ml + 700ml tap water / 4h
(stage III, IV = coma)
(massive ascites)

- Many clinical trials demonstrated the efficacy of **lactulose** in the treatment of **HE** (Dozen)
- However, one recent **metanalysis** contradicts these trials and forces the use of antibiotics particularly rifaxmin
(**BMJ, 2004**)

> Oral antibiotics

They ↓ the concentration of **ammoniagenic** bacteria →
↓ production of **ammonia** and other gut derived
neurotoxins

- **Neomycin** → 250 mg/ 2-4 times/ day
 - Its efficacy is ambiguous (**MCNA, 2008**)
 - Long term therapy → toxicity due to some systemic absorption
- **Metronidazole** + oral **Vancomycin** are little studied

- Rifaximin (xifaxan)

- non absorbable derivative of rifampin

- 400 mg orally 3TD

- Study from Texas 2008 have demonstrated that rifaximin showed superior efficacy compared with lactulose and neomycin in HE as well as better tolerability than both drugs due to minimal absorption

- Concerns → cost



◉ ↑ ammonia clearance

L-ornithine – L-aspartate (LOLA)

(Hepa- Merz, Merz Pharm-GMBH, Frankfurt Main, Germany)

- > Stable salt of 2 amino acids:
 - L-ornithine
 - L-aspartate
- > Dose: 20 gm/day/ in 250 ml of 5% dextrose water / IV infusion / 4Hs/ 5 consecutive days

(Ahmed et al 2008)

L-ornithine

L-aspartate

Glutamate

Transaminase


Glutamate ↑
+
ammonia

Glutamine

Synthetase

Glutamine

↑ clearance of ammonia



Several clinical trials

- > Kircheis et al (Hepatology, 1997)
- > Deleker et al (Hepatology, 2000)
- > Ahmad et al (Jcoll physisians surg pak, 2008)

LOLA is effective in treating HE in cirrhotic patients

Role of artificial liver supports in HE

“Liver dialysis”

○ 2 systems:

> MARS:

- molecular adsorbent recirculating system
- Albumin dialysis (AD 1999)


> Prometheus: Fractoinated plasma separation (FDPS)

- Introduced 2003

Both systems are capable of removing both water solved and albumin bound toxins without providing synthetic functions

○ Several **clinical trials** have shown that artificial liver support, is able to improve **HE** in acute and acute on chronic **liver failure**

- > Stadlbeur et al, [2008](#) (Metab brain Dis)
- > Krisper et al, [2005](#) (Hepatology)
- > Faenza et al, [2008](#) (Transplant Procedure)



- > Hassanein, T et al, 2007 (Hepatology)


MARS + Medical **Vs** Medical therapy 5 days in stage III, IV **HE**

Given complexity and **cost**, more evaluation is needed before adding this modality to the therapeutic bundle of **HE**

Liver transplantation

- Cirrhotic patients who develop severe **HE** have **poor survival** even with a fairly low **MEID** score, therefore, this constitutes a clinical indication for liver transplant evaluation
- is the **only mode** of therapy that tackles the real cause of chronic **HE** which is the lack of functioning **hepatocytes**

THANK



YOU